CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-17.65%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.32B
AUM Growth
+$1.32B
(-27%)
Cap. Flow
-$75.9M
Cap. Flow
% of AUM
-5.74%
Top 10 Holdings %
Top 10 Hldgs %
65.22%
Holding
52
New
4
Increased
6
Reduced
13
Closed
10
Top Buys
| 1 |
GH Research
GHRS
|
$15.6M |
| 2 |
Edgewise Therapeutics
EWTX
|
$15.3M |
| 3 |
ARS Pharmaceuticals
SPRY
|
$13.8M |
| 4 |
BridgeBio Pharma
BBIO
|
$13.8M |
| 5 |
MTSR
Metsera, Inc. Common Stock
MTSR
|
$10.9M |
Top Sells
| 1 |
Avidity Biosciences
RNA
|
$19.2M |
| 2 |
Arcellx
ACLX
|
$16.4M |
| 3 |
ArriVent BioPharma
AVBP
|
$15.6M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$13.4M |
| 5 |
Rhythm Pharmaceuticals
RYTM
|
$13.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $332M | 24.95% | 8,494,151 | – | – |
|
|
2
Edgewise Therapeutics
EWTX
$1.51B
| $90.2M | 6.79% | 4,101,992 +695,458 | +20% | +$15.3M |
|
|
3
BridgeBio Pharma
BBIO
$9.89B
| $69.1M | 5.2% | 2,000,000 +400,000 | +25% | +$13.8M |
|
|
4
Arcellx
ACLX
$3.85B
| $68.9M | 5.18% | 1,050,000 -250,000 | -19% | -$16.4M |
|
5
Praxis Precision Medicines
PRAX
$958M
| $66.1M | 4.97% | 1,745,000 +51,781 | +3% | +$1.96M |
|
6
NewAmsterdam Pharma
NAMS
$2.71B
| $57.8M | 4.35% | 2,825,000 -425,000 | -13% | -$8.7M |
|
7
Janux Therapeutics
JANX
$1.37B
| $54M | 4.06% | 2,000,000 -100,000 | -5% | -$2.7M |
|
8
EyePoint Pharmaceuticals
EYPT
$797M
| $45.1M | 3.39% | 8,325,000 | – | – |
|
9
Insmed
INSM
$28.8B
| $40.1M | 3.01% | 525,000 -125,000 | -19% | -$9.54M |
|
|
DRUG
10
Bright Minds Biosciences
DRUG
$276M
| $38.2M | 2.87% | 1,059,331 | – | – |
|
|
BBOT
11
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $32.9M | 2.47% | 2,909,000 | – | – |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $32.5M | 2.45% | 2,261,600 -300,000 | -12% | -$4.31M |
|
13
Merus
MRUS
$4.98B
| $31.1M | 2.34% | 740,000 | – | – |
|
|
RAPP
14
Rapport Therapeutics
RAPP
$643M
| $29.5M | 2.22% | 2,940,921 | – | – |
|
15
Axsome Therapeutics
AXSM
$6.05B
| $29.2M | 2.19% | 250,000 -75,000 | -23% | -$8.75M |
|
16
Pharvaris
PHVS
$1.39B
| $23M | 1.73% | 1,466,460 | – | – |
|
|
17
GH Research
GHRS
$837M
| $22.2M | 1.67% | 2,009,482 +1,416,439 | +239% | +$15.6M |
|
18
Arcutis Biotherapeutics
ARQT
$1.86B
| $21.1M | 1.59% | 1,350,000 -475,000 | -26% | -$7.43M |
|
19
Tarsus Pharmaceuticals
TARS
$2.47B
| $20.5M | 1.55% | 400,000 -100,000 | -20% | -$5.14M |
|
|
20
ARS Pharmaceuticals
SPRY
$1.15B
| $20.1M | 1.51% | 1,600,000 +1,100,000 | +220% | +$13.8M |
|
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $20.1M | 1.51% | 600,000 -400,000 | -40% | -$13.4M |
|
22
CG Oncology
CGON
$2.04B
| $19M | 1.43% | 775,000 | – | – |
|
|
CRGX
23
DELISTED
CARGO Therapeutics
CRGX
| $13.8M | 1.03% | 3,381,277 +2,198,714 | +186% | +$8.95M |
|
|
ABVX
24
Abivax
ABVX
$6.12B
| $13.3M | 1% | 2,130,000 | – | – |
|
|
ALMS
25
Alumis Inc. Common Stock
ALMS
$479M
| $13.2M | 0.99% | 2,147,396 | – | – |
|